Cargando…

The role of intranasal esketamine in treatment-resistant depression

INTRODUCTION: Major depressive disorder (MDD) is a highly prevalent clinical condition with a leading cause of disability worldwide. Unfortunately, about 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fraga, A., Esteves-Sousa, D., Facucho-Oliveira, J., Albuquerque, M., Costa, M., Espada-Santos, P., Moutinho, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475877/ http://dx.doi.org/10.1192/j.eurpsy.2021.1278

Ejemplares similares

Effects of psilocybin-assisted therapy on treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

The Role of Vagus Nerve Stimulation in Depression: What We Know?
por: Fraga, A., et al.
Publicado: (2022)

Mechanisms linking gut microbiota to depression
por: Fraga, A., et al.
Publicado: (2021)

The role of Mediterranean Diet in mental health in pandemic times
por: Fraga, A., et al.
Publicado: (2021)

Irritable Bowel Syndrome: The role of the Psychiatry
por: Fraga, A., et al.
Publicado: (2022)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Ketamine and Electroconvulsive Therapy: Better Together?
por: Fraga, A., et al.
Publicado: (2022)

Neuropsychiatric symptoms of multiple sclerosis: A case report
por: Dos Santos, P. Espada, et al.
Publicado: (2021)

Lithium: more than a mood stabilizier
por: Fraga, A., et al.
Publicado: (2022)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

COVID-19 Psychiatric Inpatient Unit- experience and challenges
por: Mesquita, B., et al.
Publicado: (2022)

Behavioural Variant of Frontotemporal Dementia or Mood Disorder?
por: Mesquita, B., et al.
Publicado: (2022)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
por: Martiadis, V., et al.
Publicado: (2022)

Aripiprazol and Hypersexuality: when partial is to much
por: Espada-Santos, P., et al.
Publicado: (2022)

Intranasal Esketamine administration in catatonia: a case report.
por: Romay, J., et al.
Publicado: (2023)

Mindfullness-Based Interventions for Anxiety and Depression
por: Mesquita, B. L. B., et al.
Publicado: (2023)

First episode psychosis: the depressive symptoms and suicidal behaviour that follow
por: Mesquita, B. L. B., et al.
Publicado: (2023)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
por: Martiadis, V., et al.
Publicado: (2023)

Valproate-induced hypothyroidism in schizoaffective disorder
por: Facucho-Oliveira, J., et al.
Publicado: (2022)

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021)

Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
por: Skala, Katrin, et al.
Publicado: (2023)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
por: Wattinne, E. Gaudre, et al.
Publicado: (2021)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
por: Capuzzi, Enrico, et al.
Publicado: (2021)

Transcranial magnetic stimulation and post-traumatic stress disorder
por: Moura, N., et al.
Publicado: (2022)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
por: Faisant, S., et al.
Publicado: (2022)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2021)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
por: Olivola, Miriam, et al.
Publicado: (2022)

A 28-Day, Randomized, Controlled, Single-Blind, Phase 2 Study in Treatment-Resistant Major Depressive Disorder (TRD) Patients Receiving Intranasal Esketamine Comparing Addition of Almond Therapy TM with Treatment-as-Usual (TAU)
por: Chue, P., et al.
Publicado: (2023)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022)

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
por: Basto, M. D. R. D. R. F. D. A., et al.
Publicado: (2023)

The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
por: Dijkstra, Francis M, et al.
Publicado: (2022)

How to manage antipsychotic-induced akathisia
por: Moura, N., et al.
Publicado: (2021)

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
por: Rognoni, Carla, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ga6nf9fojc76to5nirqsh6rn50